Printer Friendly

Diabetic Nephropathy Therapeutics Pipeline Analysis, 2017 by P&S Market Research.

[ClickPress, Wed Jul 26 2017]

The main growth drivers for the therapeutic pipeline of diabetic nephropathy are increasing investment in research and development of new drugs for the disease, rising prevalence of diabetes and obesity, elevated awareness about diabetes and kidney-related disorders. According to International Diabetes Federation the prevalence of diabetes worldwide is 415 million people globally and it is estimated to reach to 642 million people by 2040.

Explore Report at: https://www.psmarketresearch.com/market-analysis/diabetic-nephropathy-therapeutics-pipeline-analysis

In recent years, many big pharmaceutical companies have invested significant amount of capital on the research and development of drugs for nephropathy. In March 2017, Ironwood Pharmaceuticals, Inc. announced that it will initiate a Phase II clinical trial investigating IW-1973 in diabetic nephropathy. IW-1973 is an investigational soluble guanylate cyclase (sGC) stimulator which plays an important role in regulating diverse physiological processes such as blood flow, inflammation, fibrosis, and metabolism. The company expects that IW-1973 could generate annual peak sales of more than $5.0 billion, globally.

In 2013, AbbVie, Inc. initiated Phase III clinical trial of its investigational compound atrasentan for treatment of diabetic nephropathy. Atrasentan is a selective endothelin-A receptor antagonists, which antagonizes the effect of endothelin-l (ET-l), a peptide involved in constriction of blood vessels in the kidney.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/diabetic-nephropathy-therapeutics-pipeline-analysis/toc-sample

The major market players having drugs in pipeline for diabetic nephropathy includes Eli Lilly and Company, Reata Pharmaceuticals, Inc., Abbott Laboratories, AbbVie Inc., Bayer AG, Novartis AG, Pfizer, Inc., Mitsubishi Tanabe Pharma Corporation, and Daiichi Sankyo Co., Ltd., ChemoCentryx Inc., Mallinckrodt Pharmaceuticals and GenKyoTex S.A.

Copyright [c] 2017 ClickPress Provided by SyndiGate Media Inc. ( Syndigate.info ).

COPYRIGHT 2017 SyndiGate Media Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:ClickPress
Date:Jul 26, 2017
Words:279
Previous Article:Register Now for Vocab Tunes Biweekly Kids Dance Contest and Win an Attractive Prize.
Next Article:Immune Thrombocytopenic Purpura Therapeutics (ITP) Pipeline Analysis, 2017.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters